| Autor: |
Odetto D; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina. E-mail: diego.odetto@hospitalitaliano.org.ar., Cortez JP; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina., Saadi JM; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina., Zamora LB; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina., Riggi MC; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina., Lamm M; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina., Perrotta MB; Sección Ginecología Oncológica, Hospital Italiano de Buenos Aires, Argentina. |
| Abstrakt: |
Ovarian cancer represents the third gynecological cancer in frequency in Argentina. There is a lack of information on this pathology in our country regarding the treatment and evolution of patients who suffer it. The aim of this study was to evaluate the perioperative and oncological results in patients with advanced epithelial ovarian tumor. We present a retrospective cohort in which we evaluated disease-free survival and overall survival in patients with epithelial ovarian tumor treated at the Hospital Italiano de Buenos Aires between June 2009 and June 2017. Of 170 patients included in the study, 72 (42.4%) received primary debulking surgery (CCP), while 98 (57.6%) received neoadjuvant therapy and interval surgery (CI). The optimal cyto-reduction rate was 75% and 79% respectively. No differences were found in perioperative outcomes, or in severe complications between the two groups. The median disease-free survival in the CCP group was 2.5 years (95% CI 1.6-3.1) while in the CI group it was 1.4 (95% CI 1.2-1.7) p < 0.001. The median overall survival was 5.8 years in CPP, and 3.5 years in CI. Faced with a meticulous selection by a group of experts, patients with advanced ovarian cancer treated with CCP present better oncological results than those who received neoadjuvant therapy and CI. |
